- Home
- ATOS
as 06-11-2025 4:00pm EST
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 112.5M | IPO Year: | 2012 |
| Target Price: | $6.17 | AVG Volume (30 days): | 766.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $1.66 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Atossa Therapeutics Inc. (ATOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| QUAY STEVEN C | ATOS | President & CEO | May 21 '25 | Buy | $0.88 | 11,239 | $9,886.95 | 13,898 | |
| Remmel H. Lawrence | ATOS | Director | Mar 26 '25 | Buy | $0.70 | 10,000 | $7,000.00 | 10,257 |
Latest Atossa Therapeutics Inc. News
ATOS Breaking Stock News: Dive into ATOS Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
ACCESS Newswire
22 days ago
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
Zacks
a month ago
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
PR Newswire
a month ago
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
PR Newswire
a month ago
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update
ACCESS Newswire
a month ago
Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
a month ago
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewswire
a month ago
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
Compare ATOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATOS Atossa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.